The specter of generic challenges has long loomed above copyright’s iconic drug, Sildenafil, raising questions about the future of connected medicinal stakes. While first times saw impressive profits, the exclusivity lapse has allowed the way for less expensive alternatives, potentially lowering profitability and creating a real risk for stakehol